Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6151–6200 of 18417
Effective February 23, 2024, the Board appointed Noah Verleun to serve as the Company’s interim Chief Executive Officer following the retirement of Mr. Palmer.
and (b) the Board of Directors of the Company (the “ Board ”) appointed Joseph Tonnos as Chief Financial Officer of the Company, effective February 29, 2024.
On February 29, 2024, (a) Gordon Roth resigned as Chief Financial Officer of Roth CH Acquisition Co. (the “ Company ”)
On February 27, 2024, Jan De Witte informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process.
On February 28, 2024, Getaround, Inc.. (the “Company”) announced its Board of Directors (the “Board”) appointed Eduardo Iniguez to the position of chief executive officer, effective as of February 26, 2024.
On February 26, 2024, Matthew M. Partridge, Senior Vice President, Chief Financial Officer and Treasurer of Alpine Income Property Trust, Inc. (the “Company”), notified the Company that he will resign from his position with the Company effective April 1, 2024.
On February 26, 2024, Matthew M. Partridge, Senior Vice President, Chief Financial Officer and Treasurer of CTO Realty Growth, Inc. (the “Company”), notified the Company that he will resign from his position effective April 1, 2024.
Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).
On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.
J. Mitchell Dolloff, the Company’s President and Chief Executive Officer will oversee the Specialized Products segment on an interim basis, beginning April 2, 2024.
terminated the employment of Changhuyk Kang as the Chief Executive Officer of the Company for cause, effective immediately.
appointed TaeHoon Kim, who serves as the Chief Technology Officer and Vice President of the Company, as the interim Chief Executive Officer of the Company, effective immediately.
On February 23, 2024, William Pate announced his plans to retire as Chief Executive Officer of Par Pacific Holdings, Inc. (the “Company” or “Par Pacific”), effective as of April 30, 2024.
On February 23, 2024, the Board of Directors of Par Pacific appointed William Monteleone to become the Company’s President and Chief Executive Officer, effective upon Mr. Pate’s retirement.
Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of BioSig Technologies, Inc. (the “ Company ”) and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the Company or any of its subsidiaries, effective as of the Effective Date.
On February 27, 2024, the Board appointed former director, Frederick D. Hrkac as a director, president and principal executive officer of the Company, effective as of February 27, 2024 (the “Effective Date”), to serve for a term expiring at the next annual meeting of the Company’s stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal.
On February 28, 2024, Steven Arenal was removed as Director of the Company and Chief Executive Officer, President, and Secretary of the Company, by a Special Meeting of Shareholders.
On February 28, John D. Murphy, Jr. was reinstated as Director and President and CEO of the Company by way of a Special Meeting of Shareholders.
On February 22, 2024, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) terminated the employment of Tzur Di-Cori pursuant to which he ceased serving as the Company’s Chief Executive Officer, effective immediately.
On February 26, 2024, the Company’s Chief Financial Officer and principal accounting officer, Daniella Turenshine, notified the Company of her decision to resign effective April 12, 2024
On February 26, 2024, the Board of Directors (the “ Board ”) of the Company designated Kevin Fosty, the Company’s VP, Controller, to serve as the Company’s Interim Chief Financial Officer and principal accounting officer on an interim basis, effective as of the Effective Date
and Sridhar Ramaswamy was appointed to succeed Mr. Slootman as the Company's new Chief Executive Officer.
Effective February 27, 2024, Frank Slootman retired as Chief Executive Officer of Snowflake Inc.
C. Todd Asbury, the President and Chief Executive Officer of the Company, will step down from his current positions effective March 31, 2024.
James W. Kiser, the President and Chief Executive Officer of the Bank, will assume those same duties with the Company on March 31, 2024.
On February 26, 2024, the Board of Directors (the “Board”) of SunPower Corporation (the “Company”) accepted the resignation of Peter Faricy, the Company’s Chief Executive Officer and principal executive officer, effective as of February 26, 2024.
David A. Burwick, President and Chief Executive Officer, has decided to step down from his position and as a member of the Company’s Board of Directors, effective March 31, 2024.
assume the position of President and CEO on April 1, 2024
As of the Effective Date, Mark Mauldin will cease serving as Interim Chief Financial Officer and will continue to serve in his role as Chief Accounting Officer.
On February 27, 2024, Silicon Laboratories Inc. (the “Company”) announced the appointment of Dean Butler as Senior Vice President and Chief Financial Officer, effective May 15, 2024
Each of the Company’s directors (Darryl Porter, Landel Hobbs, Jill Krueger, Alan Aldworth, Aaron Reitkopf, Michael Friedman, Eyal Lalo, Steve Panagos, and Jill Frizzley), and the Company’s remaining officer, James Alt, will cease to be directors and officers of the Company on the Effective Date.
Effective upon Mr. Butler’s resignation, Michael Hurlston, President and Chief Executive Officer of the Company, will serve as the Company’s principal financial officer on an interim basis.
On February 21, 2024, Dean Butler, the Senior Vice President and Chief Financial Officer of Synaptics Incorporated (the “Company”), informed the Company that he has decided to resign, effective February 26, 2024.
On February 21, 2024, the Board appointed Thomas H. King to serve as Interim Chief Financial Officer, effective immediately.
On February 26, 2024, D. Andrew Borrmann, Chief Financial Officer of Southern First Bancshares, Inc. (the “Company”) and Southern First Bank (the “Bank” and together with the Company, the “Employer”), notified the Employer that he is resigning from his roles with the Employer , effective March 29, 2024 .
Mr. Carter was appointed as the Company’s Chief Financial Officer
Mr. Atwood was appointed as the Company’s Chief Executive Officer
its President and Chief Executive Officer, Michael Cammarata, and its Executive Vice President and Chief Legal Officer, John Wirt, have been placed on mandatory unpaid leave, effective February 23, 2024
the Board appointed Nirav Tolia as the Company’s Chief Executive Officer, President, and Chairperson of the Board, effective as of the Transition Date
Sarah Friar will resign from her position as the Chief Executive Officer, and President and Chairperson of the Board
Effective February 26, 2024, Benjamin G. S. Fowke, III, who has served on the Board since February 2022, was appointed Interim Chief Executive Officer and President.
On February 20, 2024, following discussions with Julia A. Sloat, Chair, Chief Executive Officer and President of American Electric Power Company, Inc. (“Company”), the Board of Directors (the “Board”) of the Company determined to remove Ms. Sloat from her roles as Chair, Chief Executive Officer and President of the Company, effective February 25, 2024.
On February 26, 2024, the Company announced that Michaela (Mika) M. Ware, 52, has been appointed to the position of Senior Vice President and Chief Financial Officer effective as of June 27, 2024.
On February 22, 2024, Joseph G. Taylor, 65, notified Brinker International, Inc. (the “Company”) that he will retire from his position of Executive Vice President and Chief Financial Officer effective as of June 26, 2024
Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).
On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).
On February 21, 2024, MarketAxess Holdings Inc. (the “Company”) appointed Ilene Fiszel Bieler as Chief Financial Officer of the Company and to act as the Company’s principal financial officer for purposes of the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), effective on her start date with the Company, which is currently expected to be May 22, 2024 (the “Effective Date”).
Effective as of immediately following the Effective Time, Mr. Dundas will be terminated from his employment as President and Chief Executive Officer of Enerplus
William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.
On February 26, 2024, Northwest Bancshares, Inc. (the “Company”) and its wholly-owned subsidiary, Northwest Bank, appointed Douglas M. Schosser Chief Financial Officer, effective March 18, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.